Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 84 Issue 4, October 2018

Bhatia et al. treated patients with steroiddependent nephrotic syndrome with rituximab, a monoclonal antibody against B lymphocytes, resulting in remission and changes in subsets of T cells. These changes reversed during relapse, suggesting that the mechanism of remission by rituximab was the changes in the T-cell subsets.

See the article on page 520.

Editor's Focus

Top of page ⤴

Editorial

Top of page ⤴

Comment

Top of page ⤴

Review Article

Top of page ⤴

Article

Top of page ⤴

Review Article

Top of page ⤴

Population Study Article

Top of page ⤴

Clinical Research Article

Top of page ⤴

Basic Science Article

Top of page ⤴

Insights

Top of page ⤴

Search

Quick links